ASI to Open Pharmaceutical Laboratory in Düsseldorf
News Oct 04, 2012
Ashland Specialty Ingredients (ASI) has announced plans to open a new pharmaceutical application laboratory in Düsseldorf, Germany, in December 2012.
“With a location central to major pharmaceutical and nutraceutical customers in the region, this new lab will enable us to offer sizable value and convenience to global multinational companies as we bring on board research projects,” said Dr. Edmont Stoyanov, technical director pharmaceutical, Europe, the Middle East and Africa, ASI.
Dr. Stoyanov continued, “In addition, it will ensure our capability to realize novel ideas and developments quickly and sharpen our R&D profile. Ultimately, this will help strengthen our position as a leading innovator and deepen our relationship with originator companies.”
The new laboratory will be outfitted with the equipment covering all the processes required for classical pharmaceutical formulation and research.
Staffed with experienced pharmaceutical experts, Ashland’s Düsseldorf lab will ensure that Ashland’s customers continue to receive the high level of technical support to which they’ve grown accustomed, and open doors to promising new opportunities.
The new laboratory will be part of Ashland’s global pharmaceutical facilities network, which includes numerous laboratories and research centers worldwide, facilitating technical assistance for drug solubilization, including hot-melt extrusion and spray drying.
“Placing Ashland’s experienced pharmaceutical experts in Düsseldorf will provide the highest level of technical support for customers in areas like granulation, coating and tableting, including direct compression, roller compaction and wet granulation,” added Stoyanov.
Stoyanov continued, “We can offer our European customers quick and detailed support on all tableting issues. The lab location in Germany will accelerate and optimize the cooperation with the R&D departments of our European customers.”
Additionally, the lab will extend its services to host hands-on applications training and technical seminars for up to 20 people at a time.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018